Erasca, Inc. Files 8-K Report
Ticker: ERAS · Form: 8-K · Filed: May 17, 2024 · CIK: 1761918
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
Erasca filed an 8-K on May 16th, check it for company updates.
AI Summary
On May 16, 2024, Erasca, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware with its principal executive offices in San Diego, California, operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides an update on Erasca, Inc.'s corporate activities and financial status, which is crucial for investors and stakeholders to assess the company's current standing.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K report, which typically contains standard corporate information and does not indicate any immediate or significant risks.
Key Numbers
- 001-40602 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-1217027 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Erasca, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
- May 16, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Erasca, Inc.?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 16, 2024.
When was the earliest event reported in this filing?
The earliest event reported was on May 16, 2024.
Where are Erasca, Inc.'s principal executive offices located?
Erasca, Inc.'s principal executive offices are located at 3115 Merryfield Row, Suite 300, San Diego, California, 92121.
What is Erasca, Inc.'s Standard Industrial Classification (SIC) code?
Erasca, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the SEC file number for Erasca, Inc.?
The SEC file number for Erasca, Inc. is 001-40602.
Filing Stats: 1,152 words · 5 min read · ~4 pages · Grade level 12.4 · Accepted 2024-05-17 06:05:03
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share ERAS NASDAQ Glo
- $1.85 — "Common Stock") at an offering price of $1.85 per Share. The Underwriters have agreed
- $1.7575 — he Underwriting Agreement at a price of $1.7575 per Share. In addition, the Company has
- $151.6 m — fering are expected to be approximately $151.6 million, or approximately $174.4 million
- $174.4 million — mately $151.6 million, or approximately $174.4 million if the Underwriters' option to purchase
Filing Documents
- d815150d8k.htm (8-K) — 30KB
- d815150dex11.htm (EX-1.1) — 203KB
- d815150dex51.htm (EX-5.1) — 13KB
- d815150dex991.htm (EX-99.1) — 8KB
- g815150g0517071700576.jpg (GRAPHIC) — 2KB
- g815150g0517073029503.jpg (GRAPHIC) — 6KB
- g815150g0517073029863.jpg (GRAPHIC) — 2KB
- 0001193125-24-141066.txt ( ) — 457KB
- eras-20240516.xsd (EX-101.SCH) — 3KB
- eras-20240516_lab.xml (EX-101.LAB) — 18KB
- eras-20240516_pre.xml (EX-101.PRE) — 11KB
- d815150d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company's current beliefs and expectations and include, but are not limited to: the Company's expectations regarding the completion of the offering and the expected net proceeds therefrom and the sufficiency of the Company's capital resources to fund operations into the first half of 2027. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of these results will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering and the Company may use its capital resources sooner than expected, as well as risks and uncertainties inherent in the Company's business described in the Company's prior filings with the SEC, including under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Item9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated May 16, 2024, by and among Erasca, Inc. and J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the several underwriters named therein 5.1 Opinio
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Erasca, Inc. Date: May 17, 2024 By: /s/ Ebun Garner Ebun Garner, General Counsel